key: cord-1054041-nuazfcz7
authors: Ni, Jun; Huang, Miao; Zhang, Li; Wu, Nan; Bai, Chun‐Xue; Chen, Liang‐An; Liang, Jun; Liu, Qian; Wang, Jie; Wu, Yi‐Long; Zhang, Feng‐Chun; Zhang, Shu‐Yang; Chen, Chun; Chen, Jun; Fang, Wen‐Tao; Gao, Shu‐Geng; Hu, Jian; Jiang, Tao; Li, Shan‐Qing; Li, He‐Cheng; Liao, Yong‐De; Liu, Yang; Liu, De‐Ruo; Liu, Hong‐Xu; Liu, Jian‐Yang; Liu, Lun‐Xu; Wang, Meng‐Zhao; Wang, Chang‐Li; Yang, Fan; Yang, Yue; Zhang, Lan‐Jun; Zhi, Xiu‐Yi; Zhong, Wen‐Zhao; Guan, Yu‐Zhou; Guo, Xiao‐Xiao; He, Chun‐Xia; Li, Shao‐Lei; Li, Yue; Liang, Nai‐Xin; Lu, Fang‐Liang; Lv, Chao; Lv, Wei; Si, Xiao‐Yan; Tan, Feng‐Wei; Wang, Han‐Ping; Wang, Jiang‐Shan; Yan, Shi; Yang, Hua‐Xia; Zhu, Hui‐Juan; Zhuang, Jun‐Ling; Zhuo, Ming‐Lei
title: Clinical recommendations for perioperative immunotherapy‐induced adverse events in patients with non‐small cell lung cancer
date: 2021-03-30
journal: Thorac Cancer
DOI: 10.1111/1759-7714.13942
sha: 527fc322e6573af5530741f4229e52d0ad7ab58a
doc_id: 1054041
cord_uid: nuazfcz7

Perioperative adjuvant treatment has become an increasingly important aspect of the management of patients with non‐small cell lung cancer (NSCLC). In particular, the success of immune checkpoint inhibitors, such as antibodies against PD‐1 and PD‐L1, in patients with lung cancer has increased our expectations for the success of these therapeutics as neoadjuvant immunotherapy. Neoadjuvant therapy is widely used in patients with resectable stage IIIA NSCLC and can reduce primary tumor and lymph node stage, improve the complete resection rate, and eliminate microsatellite foci; however, complete pathological response is rare. Moreover, because the clinical benefit of neoadjuvant therapy is not obvious and may complicate surgery, it has not yet entered the mainstream of clinical treatment. Small‐scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancellation of surgery, additional illness, and even death, and have therefore attracted much attention. In this article, we draw on several sources of information, including (i) guidelines on adverse reactions related to immune checkpoint inhibitors, (ii) published data from large‐scale clinical studies in thoracic surgery, and (iii) practical experience and published cases, to provide clinical recommendations on adverse events in NSCLC patients induced by perioperative immunotherapy.

Immune checkpoint inhibitors (ICIs) promote antitumor immunity by preventing inhibitory signaling through checkpoint receptors such as programmed death-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) expressed on T lymphocytes and their ligands programmed death ligand-1 (PD-L1) and CD80/CD86, respectively, expressed on tumor cells and other immune cells. 1, 2 ICIs have revolutionized the treatment of many cancers, including non-small cell lung cancer (NSCLC). Monoclonal antibodies that target the PD-1-PD-L1 axis (e.g., nivolumab, pembrolizumab, atezolizumab, and durvalumab) have shown efficacy in advanced NSCLC 3 and have been approved as first-and second-line treatment in many countries. In the 2017 PACIFIC study of patients with stage III unresectable NSCLC, patients treated with durvalumab after concurrent chemotherapy and radiotherapy survived significantly longer than those treated with radiotherapy and chemotherapy alone. The PACIFIC treatment regimen has become standard for stage III unresectable NSCLC. 4 Many additional clinical studies of perioperative immunotherapy are now being carried out to improve the cure rate and prolong disease-free survival (DFS) of patients with locally advanced NSCLC. 5 The goal of preoperative immunotherapy, which includes ICI monotherapy, double therapy, and chemotherapy combined with immunotherapy, is to prevent suppression and/or induce reactivation of antitumor T cells, thereby reducing the disease stage, improving the rate of complete (R0) resection, controlling microsatellite foci, and improving the overall survival (OS) rate. Phase II/III clinical studies of postoperative adjuvant immunotherapy are also underway. Among them, the NADIM and SAKK 16/14 studies 6,7 of 46 and 68 patients, respectively, with early/locally advanced NSCLC found that perioperative chemotherapy plus immunotherapy resulted in a major pathological response (MPR) rate of 60%-85%, and a complete pathological response (pCR) rate of 18.2%-71.4%. In addition, a similar study of neoadjuvant immunotherapy for stage IIIA/B NSCLC showed a significant correlation between OS and both pCR and MPR, 8 suggesting that perioperative immunotherapy may be an excellent choice for NSCLC treatment in the future.

Despite the clinical benefits of immunotherapy, it is inevitable that adverse events (AEs) will occur. Such immunotherapy-related AEs (irAEs) can be serious, and in a few cases even life-threatening, resulting in inoperability, delayed surgery, and increased postoperative complications. 9 A meta-analysis 9,10 conducted by Lung Adjuvant Cisplatin Evaluation (LACE) and NSCLC Collaborative Group showed that neoadjuvant immunotherapy reduced the risk of death in NSCLC patients by 13%. Grade 3-4 AEs were as high as 66% for both therapies; however, irAEs of pneumonia, cardiac toxicity, digestive tract toxicity, and other rare but serious toxicities seriously affected patient prognosis. 11 There is thus an urgent need for better management of irAEs, and specific steps should be embodied in procedures for baseline examination, diagnosis, differential diagnosis, and multiple disciplinary management models.

Lung cancer treatment has entered a new era, and thoracic surgery plays a vital role in the clinical application immunotherapy and the management of its adverse reactions. At present, doctors in the field of lung cancer diagnosis and treatment, especially thoracic surgeons, are facing many challenges such as reorganization of knowledge structure, and increased professional extensibility. To address these challenges, in this review, we have integrated the opinions of clinicians in many disciplines and put forward general clinical recommendations that aim to provide a relevant knowledge structure, provoke opinions, improve the conceptual diagnosis and treatment of perioperative irAEs, and provide more effective clinical guidance.

While the specific mechanisms underlying many irAEs is unclear, several potential mechanisms have been proposed, including (i) enhanced activity of T cells against antigens expressed by tumors and normal tissues, (ii) activity of existing and new autoimmune antibodies, (iii) increased production of inflammatory cytokines, and (iv) in the case of CTLA-4-CD80/CD86 checkpoint blockade, immune responses promoted by direct binding of anti-CTLA-4 antibody to normal cells expressing CTLA-4. 12 Immune attack of normal tissues can cause a range of irAEs, the most common being toxicities of the skin, endocrine system, liver, gastrointestinal tract, lungs, and skeletal muscle, and transfusion reactions. Less commonly, irAEs may also affect the nervous system, blood, kidneys, heart, and eye. 12 Based on the unique mechanism of action of ICIs, the incidence, severity, and type of irAEs differ from AEs associated with traditional chemotherapy. One report 13 noted that patients receiving immunotherapy had significantly lower rates of any grade AEs (65.8% vs. 85.2%, odds ratio [OR] 0.35), grade ≥3 AEs (16.5% vs. 41.1%, OR 0.26), rate of treatment interruption due to AEs (6.4% vs. 10 .8%, OR 0.55, 95% confidence interval 0.39-0.78), and rate of death due to treatment-related AEs (0.87% vs. 1.28%) compared with patients receiving chemotherapy. The most common irAEs of any grade were (in order of frequency) diarrhea followed by hypothyroidism, elevated aspartate aminotransferase (AST), vitiligo, and elevated alanine aminotransferase (ALT), while the most common irAEs of grade ≥3 were elevated AST and ALT, pneumonia, diarrhea, and colitis. 15 irAEs usually emerge weeks to months after initiation of ICI therapy and are generally of long duration, sometimes lasting until and beyond the end of treatment.

Several phase III clinical studies are currently investigating perioperative immunotherapy for NSCLC patients, including the CheckMate-816 (NCT02998528), KEYNOTE-671 (NCT03425643), IMpower-030 (NCT03456063), and AEGEAN (NCT03800134) trials. These studies have reported MPRs of 19%-45% for neoadjuvant ICI monotherapy, 33% for combination ICI therapy, and as high as 85% for ICI combined with chemotherapy. Phase I/II clinical studies have also demonstrated the beneficial potential of perioperative immunotherapy, although several studies 6, [14] [15] [16] reported AEs resulting in delayed surgery, altered surgery mode, reduced operative benefit, prolonged hospital stay, and increased economic burden on patients. Moreover, the incidence of perioperative complications and mortality was increased for patients with severe AEs. Therefore, careful management of lung cancer patients receiving perioperative immunotherapy should include early identification of irAEs and intervention with immunosuppressive and/or immunomodulatory agents. Guidelines from authorities such as the Chinese Society of Clinical Oncology and National Comprehensive Cancer Network (NCCN) have pointed out that prevention, assessment, examination, treatment, and monitoring of the reactions are all essential components in the overall process of irAE management.

Although the utility of immunotherapy for operable NSCLC is currently being explored, support from higher-level evidence-based medicine is needed. The results of completed studies are exciting, but the number of cases included is limited, and the high disease control rate needs to be further confirmed by larger-scale clinical studies. The possible benefits and potential risks of immunotherapy must be fully explored in clinical practice, especially in special patient populations such as those with autoimmune diseases, organ dysfunction, and transplant-associated immunosuppression to ensure the best outcomes of perioperative immunotherapy and of the surgery itself.

ICI treatment can lead to recurrence or exacerbation of existing autoimmune diseases 17, 18 and may even elicit new ones. 19 Therefore, immunosuppressed patients who are administered ICIs should be closely monitored by specialists. Before starting immunotherapy, we suggest that the dose of prednisone is reduced to <10 mg/day (or equivalent). Patients who are not suitable for immunotherapy include those with autoimmune nervous system diseases or any life-threatening autoimmune disease, particularly if their disease cannot be controlled by immunosuppressive drugs or they require large doses of immunosuppressive drugs to maintain control.

Organ and hematopoietic stem cell transplantation recipients ICI therapy may lead to graft-versus-host disease (GVHD) or failure of organ transplants. The incidence of GVHD in kidney, liver, and heart transplant patients is about 50%, 44%, and 25%, respectively. Before initiating immunotherapy, the possible outcomes should be fully discussed with the patients and transplant surgeons. Patients  who have previously received solid organ transplants and  have a feasible alternative treatment if and when graft rejection occurs may be suitable for immunotherapy if there is  no evidence of transplant rejection and they are in the maintenance treatment stage of 

As noted earlier, ICIs such as monoclonal antibodies against PD-1, PD-L1, and CTLA-4 have proven useful in the treatment of locally advanced or metastatic NSCLC, and clinical trials of adjuvant/neoadjuvant immunotherapy for operable NSCLC are underway (Tables 1 and 2) . Studies of neoadjuvant immunotherapy have mainly focused on patients with early stage (IB-IIIB) NSCLC, and no guidelines for their use as auxiliary therapy have yet been published. Patients enrolled in the clinical study can follow the screening process of the study. At present, NSCLC patients selected for neoadjuvant immunotherapy in real-world clinical practice tend to have high T stage, multiple N2 metastasis, and fusion N2 metastasis, and earlier disease stages are still being explored.The current NCCN guidelines recommend postoperative adjuvant therapy (chemotherapy, radiotherapy, or targeted therapy) for patients with completely resected (R0) NSCLC but not for patients with stage IA NSCLC; it may be considered for patients with stage IB NSCLC with high risk factors, although the recommendations lack high-level evidentiary support. Ongoing clinical trials of postoperative adjuvant immunotherapy based on the recommendation of the guidelines mainly include patients with completely resected stage IB-IIIA NSCLC (Table 3) .

For patients with incomplete resection (R1 or R2) after stage IB NSCLC, maintenance immunotherapy can be considered after postoperative adjuvant therapy if a second operation is not considered. However, there are no current guidelines for the use of ICIs as auxiliary therapy and they are not routinely used in this context at present.

Evaluation and routine screening of NSCLC patients before initiation of immunotherapy may be the most important component of irAEs management because it allows the patients likely to be most susceptible to irAEs to be identified and flagged for early intervention. Before starting ICI treatment, physicians should assess current medical history, past medical history (especially autoimmune disease, immunodeficiency disease, and special infection history), personal and family history, and general condition, and perform baseline laboratory and imaging examinations (e.g., basic chest and abdomen computed tomography, magnetic resonance imaging of the head) ( Table 4 ). All patients should be informed of the potential for immunotherapy to induce adverse reactions. When AEs occur, patients should be advised to report symptoms promptly and directly to the treatment team. Timely treatment of irAEs is needed to prevent exacerbation or deterioration of the patient's condition.

Preoperative evaluation of irAEs after neoadjuvant therapy (i)Obtain a medical history; perform a preoperative physical examination and treat patients with hypertension, diabetes, and coronary heart disease. After the condition has stabilized, surgery can be considered.

(ii)Perform routine preoperative blood analyses, including biochemistry and coagulation; correct anemia, electrolyte disorders, malnutrition, coagulation disorders, and so on. Consider surgery after the condition has improved.

(iii)Perform chest imaging and electrocardiography.

(iv)Perform fiberoptic or endobronchial ultrasound bronchoscopy.

(v)Perform standard pulmonary function tests to evaluate respiratory function.

(vi)For all baseline tests, perform re-examination as necessary for abnormal inspections.

(vii)Senior thoracic surgery experts should evaluate the indications for surgery, and if necessary, multidisciplinary consultation should be led by thoracic surgeons.

(i)Evaluate the patient's consciousness, breathing, and circulation status.

(ii)Evaluate wound healing.

(iii)Evaluate the general condition of the drainage tube.

(iv)Evaluate the patient for possible surgical complications such as difficulty in expectoration, subcutaneous emphysema, pulmonary rales, asymmetric respiratory sounds, and arrhythmia.

(v)Perform routine postoperative blood analyses, including biochemistry and coagulation, and add appropriate inspection items according to the postoperative status of the patient.

(i)Ask the patient about new symptoms or exacerbation of original symptoms; conduct a detailed and meticulous physical examination, including height, weight, physical strength scores (e.g., Eastern Cooperative Oncology Group Performance Status, Karnofsky Performance Status), and pain scores if necessary.

(ii)Perform a general and targeted inspection of suspected AEs before each systemic treatment cycle (see Table 4 ).

(iii)Imaging should generally be performed every three months after surgery to re-evaluate the primary tumor.

A new adjuvant regimen for ICIs combined with chemotherapy has been designed following several phase III clinical studies of neoadjuvant immunotherapy in NSCLC, including the CheckMate-816 (NCT02998528), KEYNOTE-671 (NCT03425643), IMpower-030 (NCT03456063), and AEGEAN (NCT03800134) trials. The same regimen also had the highest MPR/pCR rate in earlier phase I/II clinical trials. Based on these studies, neoadjuvant ICIs combined with chemotherapy should be recommended as a priority for operable patients in good physical condition (Performance Status score 0 or 1). ICI monotherapy is an important option among the many neoadjuvant therapies. For operable NSCLC with high tumor expression of PD-L1, ICI monotherapy can be considered as neoadjuvant therapy, but the actual curative effect remains to be determined in large-scale phase III clinical trials. Similarly, the benefits and safety of double ICI therapy with a PD-1/PD-L1 inhibitor and CTLA-4 inhibitor as perioperative therapy will need to be confirmed in a large-scale study. At present, there is no consensus "best course" of neoadjuvant immunotherapy for NSCLC. Most current clinical studies empirically employ neoadjuvant therapy for 2-4 cycles before surgery.

The phase III trials of perioperative immunotherapy for NSCLC tend to favor 3-4 cycles of chemotherapy plus immunotherapy preoperatively, and adjuvant therapy with or without chemotherapy postoperatively. Phase III clinical studies of immunotherapy for patients with stage IB-IIIA NSCLC with no preoperative treatment have seldom employed adjuvant chemotherapy plus immunotherapy administered concurrently, but have instead opted for sequential treatment. For example, the IMpower010 (NCT02386718) and ANVIL (NCT02595944) studies of stage IB-IIIA NSCLC patients (n = 1280 and 903, respectively) employed sequential single-immunotherapy maintenance after four cycles of standard postoperative adjuvant chemotherapy.

However, because perioperative In summary, there is currently no high-level medical evidence to support a specific regimen for perioperative immunotherapy. Preliminary results suggest that combination neoadjuvant immunotherapy plus chemotherapy results in a good pathological remission rate, but whether the high MPR/pCR rate can be transformed into survival will require confirmation in phase III clinical trials. For postoperative adjuvant therapy, the survival index is the most important evaluation standard, and most current postoperative adjuvant research will not be completed until after 2024. Before a consensus is reached, it will be necessary to further explore chemotherapy combined with ICIs, sequential chemotherapy and ICIs, and ICI monotherapy or dual therapy.

Most neoadjuvant immunotherapy is administered in 2-4 cycles. A few phase II clinical studies with small sample sizes have examined the influence of immunotherapy on surgical outcomes. The LCMC3 study 23 of 101 patients with early resectable NSCLC preliminarily reported an incidence of 29% grade 3-4 AEs after two cycles of preoperative atezolizumab. The most common AEs were fatigue, fever, anorexia, transaminase elevation, nausea, joint pain, flu-like symptoms, diarrhea, pneumonia, and anemia, but overall, the treatment was well tolerated and there were no delays in surgery. The study found no significant difference in the incidence of AEs between the two groups, including grade 3-5 AEs of hypermagnesemia (4%), hypoxemia (4%), severe diarrhea (4%), and hyponatremia (4%).

In a study to evaluate the safety of nivolumab neoadjuvant immunotherapy in patients with resectable NSCLC (stage IA-IIIA), 24 seven of the 13 patients (53.8%) were converted to thoracotomy due to hilar inflammation or fibrosis after neoadjuvant immunotherapy. The seven patients included four with stage IA NSCLC, of whom one was converted (25%). The study reported no significant differences in operation time (228 min) and blood loss (100 ml) for patients receiving neoadjuvant chemotherapy and neoadjuvant immunotherapy.

In the study 24 of nivolumab neoadjuvant immunotherapy in 20 patients with stage IA-IIIA NSCLC, the postoperative incidence of AEs was 30% (6/20) for atrial arrhythmias, and 5%

(1/20) each for myocardial infarction, pulmonary embolism, and empyema. In the NEOSTAR study described above, 15 patients treated preoperatively with two cycles of nivolumab exhibited postoperative complications of persistent lung leakage (22%), bronchopleural fistula (9%), empyema (4%), pulmonary infection (4%), and nonspecific pneumonia (4%). In the most recent report from the NADIM study of 41 NSCLC patients treated with nivolumab plus carboplatin and paclitaxel, 6 the postoperative complication rate was 17.1% and included arrhythmia, persistent lung leakage, respiratory tract infection, postoperative pain, recurrent laryngeal nerve paralysis, thrombocytopenia, postoperative pulmonary infection, lower limb cellulitis, and atrial fibrillation. These studies suggest that, overall, neoadjuvant immunotherapy for patients with operable NSCLC is relatively safe, with incidences of any-grade and ≥3 grade irAEs of 23%-57% and 4.5%-13%, respectively. However, these are mostly phase I/II exploratory studies with small sample size, short follow-up time, and incomplete data. Therefore, we do not yet have a complete picture of potential AEs related to neoadjuvant immunotherapy, and the results of large-scale, prospective, and long-term follow-up studies are still needed. Past experience and published data have revealed that patients with advanced cancer may experience many types of irAEs that can affect their prognosis. For patients with operable lung cancer, perioperative irAEs will inevitably have a profound impact on their follow-up treatment. Therefore, a comprehensive and standardized perioperative AE management plan can not only ensure smooth implementation of the overall treatment plan but also play a positive role in improving the clinical outcome of patients. The majority of lung cancer clinicians should consider adopting such management plans.

While activation of T cell function by ICIs might be expected to increase inflammatory AEs, the precise pathophysiological mechanisms of action of ICIs are not yet fully understood. As noted in the introduction, irAEs may result from the activity of autoreactive T cells, autoantibodies, or cytokines, among other possibilities. irAEs of various grades affecting many systems and organs throughout the body have been reported. In the majority of AE grading systems, grades 1-2 AEs are mild to moderate and do not require hospitalization; grade 3 AEs have obvious symptoms or worsening symptoms, are considered severe, and require hospitalization; grade 4 AEs have life-threatening and/or disabling symptoms and require intensive care (Table 5 ).

(i)Adhere to the important principle of "prevention, assessment, inspection, treatment, and monitoring" for the management of ICIs to ensure early and accurate detection, diagnosis, and treatment of irAEs.

(ii)Encourage close consultation with specialists in specific diseases; complex cases or multisystem irAEs may need to be referred to tertiary medical institutions for diagnosis and treatment, and delays in the best treatment opportunity must be avoided for critically ill patients.

(iii)ICI treatment should be suspended if irAEs of grade ≥ 2 occur; treatment can then be resumed if symptoms or/and laboratory tests are reduced to grade 1 or below. For symptoms persisting for >1 week, glucocorticoid (GC) treatment should be started.

(iv)Patients with grade 3-4 irAEs should be treated with GCs, which will generally reduce most AEs to grade 1 or below over 4-6 weeks.

(v)ICI treatment should be permanently discontinued for patients with grade 4 irAEs (or endocrine irAEs that can be controlled by nonalternative therapy). Permanent discontinuation of ICIs may be considered for patients with grade ≥2 irAEs lasting for more than six weeks, or if GC therapy cannot be reduced to <10 mg prednisone (or equivalent) within 12 weeks.

(vi)For ICIs that fail to respond to at least 72 h of intravenous GC treatment, other immunomodulators or treatment regimens should be considered.

(vii)Inactivated or attenuated vaccine preparations can be administered while patients are on ICI therapy, but administration of live vaccines is not advised.

(i)For patients receiving high-dose GC therapy (1-2 mg/kg/ day), especially shock doses, or patients with high risk factors for gastrointestinal bleeding, consider adding proton pump inhibitors or H2 receptor blockers.

(ii)For patients receiving prednisone at ≥20 mg/day for ≥4 weeks, prevention of Pneumocystis carinii pneumonia and other fungal infections must be considered.

(iii)Long-term GC therapy increases the risk of osteoporosis. Supplementation with oral vitamin D and calcium and monitoring of bone metabolism indexes is recommended, and antiosteoporosis drugs should be considered when necessary.

(iv)Patients on GC therapy should be educated to avoid crowded places or contact with infection sources by wearing personal protection (masks), washing hands frequently, and paying attention to food hygiene; and to avoid substantial weight gain by controlling food intake. Blood sugar, blood pressure, and electrolyte levels should be monitored.

GCs are steroid hormones secreted by the adrenal cortex and play important roles in regulating the development, growth, metabolism, and immune function. GCs have a spectrum of anti-inflammatory, antiallergic, antishock, and immunoregulatory properties that are mediated through transcriptional and nontranscriptional pathways. Lipidsoluble GCs enter the cell directly through the plasma membrane or via transporters and bind to the cytosolic GC receptor α (cGCR). GC binding induces a conformational change and dissociation of the cGCR from molecular chaperones such as heat shock protein 90 (HSP90), HSP70, HSP56, and HSP40. In the classical direct transactivation mechanism, the activated GCR translocates to the nucleus and binds to specific DNA sequences in the target genes known as positive or negative GC response elements. These interactions modulate the transcription of target genes, leading to upregulation or downregulation of various inflammatory and immunoregulatory mediators. Because alteration of protein expression at the level of gene transcription and translation take time, the classical genomic effect of GCs takes several hours or days to produce significant clinical effects. In the second nontranscriptional or transrepression mechanism, various activities of GCs and the GCR in the cytoplasm can result in physiological or pharmacological responses within seconds or minutes. Therefore, the T A B L E 5 Immunotherapy-related adverse event (irAE) classification efficacious properties and toxic side effects of different GCs may occur with distinct kinetics (Table 6 ). According to the pharmacokinetic characteristics of GCs, they can be divided into short-acting, medium-acting, and long-acting molecules ( Table 6 ). Most oral GCs are absorbed within 30 min and have high oral bioavailability. (1) The proliferation degree of bone marrow cells is less than 30%; (2) no severe pancytopenia; (3) at least two of the three blood components are lower than normal • Severe AA (SAA): (1) The proliferation degree of bone marrow cells is less than 25% or (2) bone marrow biopsy shows that the proliferation degree of cells is less than 50%, among which hematopoietic cells are less than 30%, and there are (1) reticulocyte count <40 000/μl; neutrophils <500/μl; PLT < 20 000/μl The most effective treatment of irAEs depends on the early initiation of GC therapy. Overall, guidelines on GC dosage and regimen are similar in Japan and the rest of the world, although some details differ (Table 7 ). In general, GCs or immunomodulators are not recommended for grade 1 irAEs, and ICI therapy can be continued. ICIs should be suspended for grade ≥2 irAEs, and local or systemic treatment with a moderate dose of GC (0.5-1 mg/kg/day) is recommended. For irAEs of grade 3 or 4, ICIs should be permanently withdrawn, and systemic treatment with a large dose, or even shock dose, of a moderate-effect GC is suggested. Immunomodulators or other treatments can be added according to persisting symptoms within 3-5 days of GC administration.

IVIG consists of blood components, mainly immunoglobulins, purified from pooled normal human plasma, and it is used to treat a variety of disorders. The mechanisms of action of IVIG are complex, but their immunomodulatory activities depend predominantly on the portion of the antibody involved. The antigen-binding portion of immunoglobulins is composed of the variable regions of the two light and two heavy chains and is known as the F(ab')2 region, whereas the opposite termini of the two heavy chains make up the constant (Fc) portion of the molecule. IVIGmediated immunoregulation may occur via antigen binding by the F(ab')2 domains or Fc receptor binding by the Fc domains, and can result in inhibition of pathogenic autoantibody production, complement production, T cell activation, and cytokine production, among other mechanisms. IVIG is widely used in the treatment of various severe irAEs and autoimmune/inflammatory diseases, including Guillain-Barré syndrome, myasthenia gravis, bullous rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, thrombocytopenia, and others.

For the first treatment, IVIG can be administered at 2 g/ kg several times over 3-5 days. At present, a widely used course of treatment in the clinic is 400 mg/kg/day for 3-5 days, and this can be repeated if the irAE recurs. IVIG should be administered slowly, starting at 1 ml/min and not exceeding 3 ml/min, and should not be mixed with other drugs. Once the vial is opened, it should be infused at once and unused portions discarded.

IVIG is a relatively safe drug with a low (1%) incidence of side effects. Common AEs include headache, back pain, nausea, vomiting, diarrhea, facial flushing, fever, chills, shortness of breath, chest tightness, hypotension, hypertension, and rash. AEs are mostly transient, usually occur during the first or second infusion, and are generally related to rapid intravenous administration and the use of preparations from different manufacturers. A slow infusion rate can alleviate such reactions. In rare cases, a low dose of GC or an antihistamine should be given 30 min before infusion. Because IVIG contains a small amount of IgA, its use in patients with congenital IgA deficiency should be strictly monitored/prohibited due to the risk of allergic reactions.

The use of long-term medium-dose or high-dose GCs for perioperative therapy may increase infection or delay healing. After multidisciplinary discussion, one of several alternative therapeutic methods may be implemented for the prompt treatment of severe irAEs.

(i) For severe irAEs that do not respond to GC treatment within 48-72 h, treatment with TNF-α inhibitors can be started immediately. Infliximab 5 mg/kg is a standard treatment, and there are also case reports using adalimumab and etanercept.

(ii) Patients receiving GC and infliximab or FDAapproved biological analogues should be closely monitored and followed up. A second anti-TNF-α treatment can be considered as needed; if so, it can be administered twice at two weeks and six weeks after the first inhibitor.

(iii) Because infliximab could potentially reactivate HBV and HCV, patients should be screened for HBV and HCV before treatment with a TNF-α inhibitor, and HBV/HCV carriers should be monitored during and for several months after treatment.

(iv) Similarly, infliximab may also reactivate tuberculosis, and patients should therefore be tested before initiation of TNF-α inhibitors. If treatment is urgent, there is no need to wait for the tuberculosis test results.

(i) For severe irAEs that do not respond to GC treatment within 48-72 h, an IL-6R inhibitor (e.g., tocilizumab 4-8 mg/kg) can be started immediately. Treatment can be repeated 8 h later as needed, with a maximum of three doses in 24 h.

(ii) IL-6R inhibitors should be used with caution in patients with chronic or recurrent infections. For patients with tuberculosis, invasive fungal, bacterial, viral, and other opportunistic infections, adequate anti-infection treatment should be given before tocilizumab administration. Hematological indexes and liver and kidney function should be closely monitored during treatment.

Anti-CD20 monoclonal antibody CD20 is a transmembrane protein encoded by the MS4A1 gene and is expressed on the surface of B lymphocytes. CD20 is a marker of pre-B to mature B cells, but it is not expressed on hematopoietic stem cells, progenitor B cells, or mature plasma cells. The mechanism of tumor cell killing by anti-CD20 monoclonal antibodies (e.g., rituximab) includes antibody-and complement-dependent cell mediated cytotoxicity and direct intracellular signaling through CD20 that affects cell growth, cell cycle progression, and apoptosis.

At present, the NCCN guidelines recommend rituximab for the treatment of GC-resistant bullous dermatitis at 1000 mg once every two weeks for four weeks followed by 500 mg every 12 or 18 months. For the treatment of refractory nerve damage (myasthenia gravis, aseptic meningitis, encephalitis), rituximab is recommended at 375 mg/m 2 once weekly for four weeks or 500 mg/m 2 once every two weeks for four weeks.

MMF is a prodrug that is converted to mycophenolic acid after oral consumption. The active metabolite inhibits hypoxanthine nucleoside phosphate dehydrogenase, which reduces guanine nucleotide synthesis and selectively inhibits the proliferation and function of T and B lymphocytes, resulting in suppression of the immune response.

For the treatment of irAEs such as refractory hepatitis, pneumonia, and bullous diseases, MMF can be administered twice at 1-2 g/day orally, and the amount can be adjusted in consultation with specialists according to changes in the patient's symptoms. Gastrointestinal reactions are possible side effects of MMF and can be alleviated by drug dose reduction or discontinuation. MMF has teratogenic effects and long-term use can lead to opportunistic infections.

Cyclosporine is an 11-amino acid cyclic polypeptide originally identified in fungal extracts. The molecule binds intracellularly to cyclophilin to form a complex that modulates mitochondrial activity and inhibits calcineurin, which is crucial for IL-2 production. Thus, cyclosporine not only inhibits T cell function but also affects B cell differentiation.

Current guidelines for the treatment of aplastic anemia, refractory kidney damage, and refractory nerve damage caused by ICIs are two doses of 4-5 mg/kg/day taken orally 12 h apart, followed by a slow decrease to 2-3 mg/kg/day upon improvement of the irAE.

For patients with elevated serum creatinine, an initial dose of 2.5 mg/kg/day should be used and reduced to 0.5-1.0 mg/kg/day if serum creatinine rises to 30% higher than baseline during treatment. The plasma concentration of cyclosporine should be monitored carefully to ensure it remains within the safety window of 100-200 ng/ml.

Cyclosporine can cause changes in the structure and function of tubulointerstitial and renal blood vessels, leading to nephrotoxicity such as renal interstitial fibrosis, hyaline degeneration of blood vessels, and glomerulosclerosis. Acute nephrotoxicity, which is closely associated with the decline in hemodynamics, can be reversed slowly after drug reduction or withdrawal. Cyclosporine should not be administered to patients with varicella, herpes zoster, and other viral infections.

During plasma exchange, plasma is removed from the patient's whole blood by membrane or centrifugal separation to remove pathogenic factors (e.g., toxic drugs, cytokines, inflammatory mediators). Normal plasma or other substitutes are then added back and the reconstituted blood is reinfused into the patient. Plasma exchange can thus temporarily restore immune function by removing factors that inhibit cellular and humoral immunity. While plasma exchange is not an etiological treatment for most diseases, it can rapidly reduce the concentration of pathogenic factors, including drugs, thus providing at least temporary relief from the disease-or irAErelated damage. Current NCCN guidelines recommend plasmapheresis, usually as second-line treatment, for nervous system diseases such as myasthenia gravis, Guillain-Barré syndrome, immune encephalitis, transverse myelitis. The success rate of plasmapheresis for the treatment for severe or rapidly progressing nervous system irAEs is variable. For example, hypotension may occur within 1 h after the start of the cardiopulmonary bypass due to excessive volume or low colloid osmotic pressure of the reinfusion. Because of the requirement for heparin anticoagulation, bleeding, hematoma, and gastrointestinal bleeding may occur at the puncture site after 30 min of cardiopulmonary bypass. Plasma separation and pipeline blockage may occur during cardiopulmonary bypass in elderly patients, patients with insufficient heparin dosage or poor blood flow, and upon blood flow slowing or interruption. Patients allergic to heparin and protamine should not undergo plasma exchange.

Other drugs, including cyclophosphamide, methotrexate, sulfasalazine, leflunomide, and eltrombopag, are also used to treat irAEs. However, their use has mostly been reported as individual case studies, and there is no consensus or opinion on diagnosis and treatment. After multidisciplinary discussion, these drugs may be useful for the treatment of some refractory irAEs in clinical practice.

Once ICI treatment is started, the possibility of irAEs should be monitored throughout the patient's care, including during dynamic symptom management and examinations during treatment, and long-term follow-up after treatment.

Comprehensive evaluations should be performed during ICI treatment to ensure the early detection and prompt treatment of irAEs (Table 4 ). Some immunotherapy-related toxicities may not emerge until after treatment cessation, especially those affecting renal and pituitary function. Current guidelines suggest that patients should be monitored and followed up for at least 1 year after ICI treatment.

As for ICIs, regular patient evaluation is necessary to detect symptoms and signs of irAEs after treatment with GCs or other immunomodulators; this is especially important due to the potential for opportunistic infections. Current guidelines suggest that symptoms and signs should be monitored for early indicators of irAEs at least every 72 h, and the treatment plan should be adjusted accordingly. For critically ill patients, the evaluation interval should be further reduced to every 24 or 48 h.

The risk of side effects in patients receiving GCs correlates positively with the GC dose and course, with the lowest risk occurring with low-dose and short-duration regimens. Upon first use of GCs, neuropsychiatric symptoms such as water and sodium retention, electrolyte disturbance, increased heart rate, and increased blood pressure may emerge after about three days; increased blood sugar at 1 week; opportunistic infections at ≥3 weeks; fungal infections and osteoporosis at ≥8 weeks; and endocrine diseases such as Cushing's syndrome and adrenal cortex function suppression at >12 weeks. Activation of new or latent infection must be closely monitored during treatment with GCs and immunomodulators (Table 8) .

Neoadjuvant chemoradiotherapy vesus chemotherapy alone followed by surgery for resectable stage III non-small-cell lung cancer: a meta-analysis

Neoadjuvant and adjuvant therapy for stage III non-small cell lung cancer

Immunotherapy in NSCLC: a promising and revolutionary weapon

Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC

Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): a phase II multicenter exploratory study-final data of patients who underwent surgical assessment

SAKK 16/14: anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)-a multicenter single-arm phase II trial

Pathologic complete response after induction therapythe role of surgery in stage IIIA/B locally advanced non-small cell lung cancer

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis

Immune-related adverse events associated with immune checkpoint blockade

Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials

Surgical outcomes of a multicenter phase II trial of neoadjuvant atezolizumab in resectable stages IB-IIIB NSCLC: update on LCMC3 clinical trial

Surgical outcomes following neoadjuvant nivolumab or nivolumab plus ipilimumab in non-small cell lung cancer -NEOSTAR study

Neoadjuvant PD-1 inhibitor (sintilimab) in NSCLC

Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series

Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Safety and efficacy of PD-1 inhibitors among HIVpositive patients with non-small cell lung cancer

PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV

Neoadjuvant atezolizumab in resectable non-small cell lung cancer(NSCLC):interim analysis and biomarker data from a multicenter study (LCMC3)

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. The Lancet Oncology

Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. Thorac Cancer

Peking Union Medical College Hospital)

Chinese Academy of Medical Sciences and Peking Union Medical College), Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital

Peking Union Medical College Hospital), Xiao-Xiao Guo (Peking Union Medical College Hospital

Wei Lv (Peking Union Medical College Hospital), Xiao-Yan Si (Peking Union Medical College Hospital), Han-Ping Wang (Peking Union Medical College Hospital), Jiang-Shan Wang (Peking Union Medical College Hospital), Shi Yan (Peking University Cancer Hospital), Hua-Xia Yang (Peking Union Medical College Hospital

Secretary Xiao-Xia Cui (Peking Union Medical College Hospital)

Meng-Zhao Wang (Peking Union Medical College Hospital), Chang-Li Wang(Tianjin Medical University Cancer Institute and Hospital

The authors have no potential conflicts of interest to disclose.